Glass bottles found to have five to 50 times as many microplastics as plastic bottles in shocking new study
Microplastics are everywhere — in your chewing gum, your beauty products and even your favorite junk food.
Given the name, it's reasonable to assume you're more likely to find them in products containing plastic than not.
Advertisement
3 Microplastics are everywhere — in your chewing gum, your beauty products and even your favorite junk food.
SIV Stock Studio – stock.adobe.com
But a jaw-dropping new study — published in the Journal of Food Composition and Analysis — has discovered quite the opposite seems to be the case.
Guillaume Duflos, research director at French food safety watchdog ANSES, told AFP that his team set out to 'investigate the quantity of microplastics in different types of drinks sold in France and examine the impact different containers can have.'
Advertisement
Much to their surprise, they found that glass-bottled beverages — including lemonade, iced tea, beer and soda — had five to 50 times more microplastics than their plastic or metal counterparts.
Needless to say, the team 'expected the opposite result,' study co-author Iseline Chaib told AFP.
Researchers found an average of roughly 100 microplastic particles per liter in these glass bottles, which they pinned on the paint on their caps.
3 Glass-bottled beverages had five to 50 times more microplastics than their plastic or metal counterparts.
SKfoto – stock.adobe.com
Advertisement
'We…noticed that in the glass, the particles emerging from the samples were the same shape, color and polymer composition — so, therefore, the same plastic — as the paint on the outside of the caps that seal the glass bottles,' Chaib said.
They theorized that 'tiny scratches, invisible to the naked eye, probably due to friction between the caps when there were stored,' might subsequently 'release particles onto the surface of the caps.'
Still, some of the study's findings remain a mystery.
3 Bottles of wine contained very few microplastics, even when capped.
Gary Perkin – stock.adobe.com
Advertisement
The team found only 4.5 particles and 1.6 particles of microplastics per liter in glass and plastic bottles, respectively.
And — in more good news — bottles of wine also contained very few microplastics, even when capped.
In contrast, there were 60, 40 and 30 microplastics per liter in beer, lemonade and soft drinks, respectively.
Duflos admitted that the reason behind this inconsistency 'remains to be explained.'
While the full health impact of microplastics continues to be unclear, studies have linked them to inflammation, hormone disruption, DNA damage, respiratory illnesses, heart problems and certain cancers.
ANSES suggests a quick fix: try blowing on the caps and rinsing them with water and alcohol.
The French watchdog found this method can slash plastic contamination by 60 percent.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 hours ago
- Business Wire
CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the initiation of a call for public tenders (buyers or investors) 1 as part of the receivership procedure 2 opened on July 1, 2025. A notice will be published in 'Les Echos' French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court 3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital version of the newspaper as early as July 3, 2025 in the evening. People interested and willing to take part in the call for public tenders are invited to get in touch with Mr Valentin Laigneau (AJRS): It is reminded that CARMAT's operations carry on during the observation period, and that CARMAT continues to endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will continue to be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 « Appel d'Offres (recherche de repreneurs ou d'investisseurs ») 2 « Redressement judiciaire » 3 « Tribunal des Affaires Economiques de Versailles (France) »
Yahoo
a day ago
- Yahoo
Israeli quantum startup Qedma just raised $26 million, with IBM joining in
Despite their imposing presence, quantum computers are delicate beasts, and their errors are among the main bottlenecks that the quantum computing community is actively working to address. Failing this, promising applications in finance, drug discovery, and materials science may never become real. That's the reason why Google touted the error correction capacities of its latest quantum computing chip, Willow. And IBM is both working on delivering its own 'fault-tolerant' quantum computer by 2029 and collaborating with partners like Qedma, an Israeli startup in which it also invested, as TechCrunch learned exclusively. While most efforts focus on hardware, Qedma specializes in error mitigation software. Its main piece of software, QESEM, or quantum error suppression and error mitigation, analyzes noise patterns to suppress some classes of errors while the algorithm is running and mitigate others in post-processing. Qedma's co-founder and chief scientific officer, Professor Dorit Aharonov, once described as a member of 'quantum royalty' for her and her father's contributions to the field, said this enables quantum circuits up to 1,000 times larger to run accurately on today's hardware, without waiting for further advancements on error correction at the computer level. IBM itself does both quantum hardware and software, and some of its partners, like French startup Pasqal, also develop their own hardware. But it sees value as well in partnering with companies more narrowly focusing on the software layer, like Qedma and Tiger Global-backed Finnish startup Algorithmiq, its VP of Quantum, Jay Gambetta, told TechCrunch. That's because IBM thinks driving quantum further requires a community effort. 'If we all work together, I do think it's possible that we will get scientific accepted definitions of quantum advantage in the near future, and I hope that we can then turn them into more applied use cases that will grow the industry,' Gambetta said. 'Quantum advantage' usually refers to demonstrating the usefulness of quantum over classical computers. 'But useful is a very subjective term,' Gambetta said. In all likelihood, it will first apply to an academic problem, not a practical one. In this context, it may take more than one attempt to build consensus that it's not just another artificial or overly constrained scenario. Still, having a quantum computer execute a program that a classical computer can't simulate with the same accuracy would be an important step for the industry — and Qedma claims it is getting closer. 'It's possible that already within this year, we'll be able to demonstrate with confidence that the quantum advantage is here,' CEO and co-founder Asif Sinay said. With a doctorate in physics, Sinay previously worked as a physicist at Magic Leap, then a multi-billion-worth AR company with a large R&D center in Israel. Like the founders of several Israeli startups, from Metacafe to Wiz, he is also a Talpion — an alum from Israel's elite military program Talpiot, where one of his classmates was Lior Litwak. Litwak is now a managing partner at Israeli VC firm Glilot Capital Partners, which led Qedma's $26 million Series A through its early growth fund, Glilot+, which he heads. The round included participation from existing investors such as TPY Capital, which backed Qedma's $4.7 million seed round in 2020, as well as new investors including Korean Investment Partners — and IBM. Since last September, Qedma has been available through IBM's Qiskit Functions Catalog, which makes quantum more accessible to end users. Sinay noted the synergies between the two companies, but emphasized that Qedma's plans are hardware-agnostic. The startup has already conducted a demo on the Aria computer from IonQ, a publicly listed U.S. company focused on trapped ion quantum computing. In addition, Qedma has an evaluation agreement with an unnamed partner Sinay described as 'the largest company in the market.' Recently, it also presented its collaboration with Japan's RIKEN on how to combine quantum with supercomputers. The joint Q2B Tokyo presentation was co-delivered by Qedma's CTO and third co-founder, Professor Netanel Lindner. An associate professor of theoretical physics and research group lead at Technion, he told TechCrunch he is hoping that some of his former doctorate students — or others they know — will join Qedma as part of the startup's hiring efforts. According to Sinay, Qedma will use the proceeds from its latest funding round to grow its team from around 40 to between 50 and 60 people. Some of these new recruits will be researchers and software engineers, but he said the startup also plans to hire for marketing and sales roles. 'We are selling our software to the end users, and our partners are the hardware manufacturers.' For hardware manufacturers like IBM, this software layer addresses the fact that a quant at a bank or a chemist who could leverage quantum are not experts in how to run circuits in the presence of noise. However, they know their respective domains and the conditions they want to set. 'So you want to be able to write the problem and say, I want it to run with this accuracy, I'm OK with this much usage of a quantum computer, and this much usage of a classical computer,' Gambetta said. 'They want [these] to be essentially little options that they can put into their software; and that's exactly what Qedma is doing, as well as some of [the] other partners we're working with.' Some researchers are already taking advantage of this via Qiskit Functions, or through partnerships that research institutions have established with Qedma and its industry peers. But the debate is still open as to when these experiments will become larger, and when quantum advantage will materialize for the broader world. Qedma hopes to accelerate the timeline by providing a shortcut. Unlike error correction at the computer level, which adds overhead that limits scalability, Qedma's approach doesn't require more quantum bits, or qubits. 'Our claim is that we can get quantum advantage even before a million qubits are achieved,' Lindner said. However, other companies are approaching that issue from different angles. For instance, French startup Alice & Bob raised $104 million earlier this year to develop a fault-tolerant quantum computer whose architecture relies on 'cat qubits,' which are inherently protected against certain errors, reducing the need for more qubits. But Qedma is not dismissive of the race for more qubits; since it acts as a booster either way, its team wants hardware to have as many qubits as possible, and the best qubits possible. In practice, though, it will be hard to maximize both at once, just like software-based error mitigation typically means longer runtimes. The best choice will depend on the specific task — but first, quantum will have to get to those tasks.
Yahoo
a day ago
- Yahoo
Venus Williams Opens Up About Her 30-Year Fibroids Journey
Collage: Self; Source images: Venus Williams, Paper Whistle, anlomaja With four Olympic gold medals, seven Grand Slam titles, and over $42 million in prize money under her belt, Venus Williams is one of the most successful athletes in history. But behind closed doors, she has been fighting a painful battle for decades that far too many Black women know well: uterine fibroids. 'I remember playing my first French open, at the time I was 16,' Williams shares with SELF over Zoom from her home in Florida. 'Before the second round, I was waiting for my match and I was just hugging the toilet bowl. I was losing my lunch over period pains.' But who would have guessed? Just moments prior—adorned in an iconic silver getup, her braids covered in white beads—Williams was on her A-game, defeating Japan's Naoko Sawamatsu in the first round of the 1997 tournament. 'Those are the things behind the scenes you don't see,' she says. For as long as she can remember, the now 45-year-old tennis star has had painful periods—one of the most common symptoms among women who suffer from fibroids, or noncancerous growths in or on the uterus that can cause heavy menstruation and intense discomfort. Yet Williams can't even recall getting a formal diagnosis. 'I think I just kind of diagnosed myself,' she shares. While her gynecologist eventually confirmed that she did, indeed, have fibroids in 2016, her pain was treated as a routine side effect of the condition. 'They would tell me we'll just watch it,' she shares. The only treatment option made available to her was a hysterectomy, and Williams held off. Williams was never offered any other clear pathway to finding relief—even as the agony from her fibroids was getting worse. By her mid-30s, she says, she was taking prescription pain killers to find some sort of ease. 'I had those pills with me everywhere,' Williams says. 'I could never be caught anywhere without my pain pills. Getting caught in that kind of pain is a disaster.' Beyond the physical pain from her fibroids, the mental anguish took a toll as well. Williams's periods became so heavy that anywhere she went, she would have to pack extra pads, tampons, fresh underwear, and a change of clothes. 'It was always an 'accident run' to the bathroom,' she remembers. 'At times you're like, Oh my God, I have to clean my pants. You have to take them off at a restaurant, wash them out—crazy stuff. That's not normal.' By 2024, Williams knew it was time to advocate for herself—something her previous doctor never seemed to do, although she shares she has no interest in placing blame anywhere. The women's health space was revolutionizing: New models were popping up that made care more accessible and inviting. (Think easy-to-navigate millennial-friendly women's medical startups like Tia and Midi.) One day while scrolling Instagram, Williams saw an ad for a fibroid clinic that detailed promising treatment options for women just like her, which made her realize that she had options. The times were changing. Eventually Williams found Taraneh Shirazian, MD, a board-certified gynecologist and director of the Center for Fibroid Care at NYU Langone. 'It was amazing for me because I was able to talk to someone who felt confident that they could treat me,' Williams says. Unlike many medical professionals in the US, Dr. Shirazian takes a holistic, personalized approach to fibroid treatment, viewing it as a chronic ailment that needs continuous care rather than something to vaguely monitor—or, on the other hand, treat with a one-and-done surgery. As part of her model, Dr. Shirazian also looks at how the condition affects other aspects of a patient's life, like fertility and general discomfort. For Williams, this led to a more comprehensive diagnosis: The athlete learned that she also had an adenomyoma, which meant in addition to her fibroids, the lining of her uterus was growing into her uterine wall. 'I was the first person to ever tell her [of the condition],' Dr. Shirazian tells SELF. 'I could tell when I said it that she never heard about the adenomyoma before, and when you hear something for the first time, you need time to really understand it, think about it, and come to terms with what you want to do.' Williams shares that while it felt good to be informed, she left the office terrified. 'For the first time in my life ever, [I thought,] Why me? Why do I have to [go through] this?' There were a few courses of treatment Williams could take, according to Dr. Shirazian: Uterine-sparing surgery, which would remove the fibroids but leave the uterus in place, would be the best option, though radiofrequency treatments could also help shrink the fibroids and relieve some pain. Though trepidatious, Williams opted for the surgery. 'Surgery completely removes disease,' the gynecologist explains. '[Venus] had been suffering for all that time. Obviously we always need to be monitoring, but given her personal history, her symptoms, and again, just with that eye on what would be good for her specifically, we arrived at that conclusion.' 'I just remember I went into the [operating room] and I started to get a little afraid again,' Williams recalls. '[Dr. Shirazian] held my hand and I was out. I don't remember much after that, but I remember she held my hand, and that meant so much.' The surgery took place in July 2024. It was a success, and Williams had no complications. Within a day or two, she was up and moving around. By day 30 of her post-op recovery, she fully felt like herself again—just without the excessive bleeding and pain. At last, after decades of suffering, Williams felt relief—within just three months of meeting Dr. Shirazian. 'I went through a lot, and you would imagine that I would have access to the best health care—and I did. But I still didn't have the best health care [until I went to NYU],' Williams shares. With anywhere from 40% to 80% of people with a uterus being likely to develop fibroids by 50—with Black women three times more likely to get them, and get them at a younger age compared to white women—Williams's hope is that sharing her story will encourage others to seek the help they may not realize they need. 'As a patient, you have to be your own advocate,' she explains, noting the serious flaws in the US healthcare system. 'If you don't know what's wrong with you in the first place, you never even know to bring it up.' But being aware of what's happening with your body and having the ability to advocate for yourself, especially as a Black woman, is only half the battle. A 2022 Pew Research Center study found that 55% of Black Americans 'have had negative experiences with doctors.' A 2024 study found that 58% of Black women, in comparison to 44% of Black men, believe that the country's health care system was designed to hold them back. Of course, this is all happening in the context of our medical establishment's racist history: For many years, the US carried out nonconsensual medical experiments on African Americans, which may also lead to lingering distrust today. Dr. Shirazian hopes to remedy as much of this as she can through working with grassroots organizations in the Black community. The MD currently partners with The White Dress Project, a patient advocacy group that raises awareness about uterine fibroids through education and research. 'They share information on doctors and hospitals to go to who are giving good services and good care [throughout the country],' Dr. Shirazian says. By being one of the few MDs in the country taking a true holistic approach to fibroid treatment—from providing personalized care to bridging the knowledge gap by working with local organizations—Dr. Shirazian hopes that other medical facilities will follow her lead. 'Sometimes that's how you get bigger institutions to sort of take notice,' she shares. '[Our approach is] innovative and revolutionary, and whatever we can say that helps [other doctors] understand that these are priorities, that's my goal.' It's now been a year since Williams's surgery. She is happy and fully free from the pain that took over her life for nearly 30 years. But most of all, she wants to make sure this isn't any other woman's story. 'Make sure you have a doctor that believes in you and that you believe in [them], that's important,' she says. 'You don't have to settle at all.' Related: Jennie Garth on Having Hip Replacements at 48 and 52: 'I No Longer Want to Hide Things' Jamie-Lynn Sigler Was in Denial of Her MS for 15 Years: 'If I Didn't Talk About It, It Wasn't Real' What to Do If Your Doctor Isn't Taking Your Period Pain Seriously Get more of SELF's great service journalism delivered right to your inbox. Originally Appeared on Self
